12:00 AM
Jan 23, 2012
 |  BC Week In Review  |  Company News  |  Other News

Alnylam endocrine/metabolic, hematology news

Alnylam said it will restructure and reduce headcount by 61 (33%) to about 115 to focus on development of its ALN-TTR and ALN-APC programs. The programs are part of Alnylam's 5x15 strategy aimed at moving five RNAi therapeutic programs into clinical development by 2015. The company said it plans to partner the remaining three programs, ALN-PCS, ALN-HPN and ALN-TMP, prior to conducting additional clinical testing. The cuts, which will come from across the company, are expected to save about $20 million in 2012.

Read the full 449 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >